Volume 1 Supplement 1

17th International Symposium on Intensive Care and Emergency Medicine

Open Access

Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: a controlled study in critically ill patients

  • P Sorkine1,
  • H Nagar1,
  • A Weinbroum1,
  • A Setton1,
  • E Israitel1,
  • A Scarlatt1,
  • A Silbiger1,
  • V Rudick1,
  • Y Kluger1 and
  • P Halpern1
Critical Care19971(Suppl 1):P040

DOI: 10.1186/cc46

Published: 1 March 1997

Objective

To evaluate the differences in administered in a lipid emulsion compared to amphotericin B (AmpoB) in dextrose 5%, for the treatment of Candida albicans infection.

Sixty consecutive critically ill patients with confirmed or suspected Candida infection received AmphoB (1 mg/kg/24 h) administered randomly in either dextrose 5% (group A) or in lipid emulsion (20% Intralipid®) (group B).

Measurements and main results

Clinical tolerance (fever, chills, hemodynamics), liver function tests, electrolytes and coagulation profile were evaluated. Patients receiving AmphoB in lipid emulsion experienced a lower incidence of drug-associated fever (61.4% versus 5.8%, P < 0.003), rigors (54% versus 8.5%, P < 0.004), hypotension (17% versus 0%) and nephrotoxicity. Significant thrombocytopenia (264,500 ± 71,460/mm3 to 163,570 ± 34,450/mm3, P < 0.01), not associated with active bleeding, occurred with AmphoB-lipid emulsion but not with the dextrose regimen.

Conclusions

Treatment with AmphoB-lipid emulsion of critically ill patients with Candida infection seems to be safer and as effective as the conventional mode of administration.

Authors’ Affiliations

(1)
Departments of Anesthesiology and Surgery, Sourasky Medical Center, Tel Aviv University

Copyright

© Current Science Ltd 1997

Advertisement